D. Western Therapeutics Institute, Inc.
🇯🇵Japan
Open-Label Study of Safety of H1337 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Glaucoma Open-Angle PrimaryOcular Hypertension
- Interventions
- Drug: H-1337 1.0%
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- D. Western Therapeutics Institute, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT06572397
- Locations
- 🇺🇸
Eye Research Foundation Inc., Newport Beach, California, United States
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 2
Active, not recruiting
- Conditions
- Ocular HypertensionGlaucoma Open-Angle Primary
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- D. Western Therapeutics Institute, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05913232
- Locations
- 🇺🇸
Global Research Management, Glendale, California, United States
🇺🇸Central Florida Eye Associates, Lakeland, Florida, United States
🇺🇸Shettle Eye Research, Inc., Largo, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath